Sensyne joins GOSH for clinical AI research in childhood diseases
OXFORD, U.K: Sensyne Health plc has signed a five year non-exclusive Strategic Research Agreement (SRA) with Great Ormond Street Hospital for Children NHS Foundation Trust...
Sensyne Health signs strategic research agreement with St. Luke’s University Health Network
DELAWARE: Sensyne Health plc (LON: SENS) has signed its first Strategic Research Agreement (SRA) in the United States of America with St. Luke’s University Health...
Sensyne Health and Royal Wolverhampton sign strategic research agreement
OXFORD: Sensyne Health plc has signed a five year non-exclusive Strategic Research Agreement (SRA) with The Royal Wolverhampton NHS Trust. The agreement will enable the...
Sensyne Health launches first digital health product in the U.S.
OXFORD: Sensyne Health plc has launched GDm-Health, its remote monitoring solution for diabetes in pregnancy, in the U.S. with immediate effect. Sensyne’s sales and marketing...
Sensyne Health and Somerset NHS Foundation Trust sign strategic research agreement
OXFORD: Sensyne Health plc has signed a five year non-exclusive Strategic Research Agreement (SRA) with Somerset NHS Foundation Trust, a news release said. The agreement...
Sensyne Health signs research collaboration agreement with Bristol Myers Squibb
OXFORD: Sensyne Health plc, the UK Clinical AI company, has signed a research collaboration agreement with Bristol Myers Squibb (BMS). Initially the collaboration will focus...
Sensyne Health Partners with Bayer
OXFORD, UK: Sensyne Health plc, the British clinical AI technology company, has joined Bayer’s LifeHub UK in an extension of its existing collaboration with Bayer...